The Aim of the Study is to Check Whether Follicular Fluid Evaluation Using a Spectrophotometer Can Differentiate High Quality Oocytes From Low Quality Oocytes. Oocyte Quality Will be Defined Using GDF9, BMP15 and Oocyte Morphology.
NCT ID: NCT07329998
Last Updated: 2026-01-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
200 participants
INTERVENTIONAL
2024-09-22
2026-11-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Markers in Follicular Fluid and in Embryo Culture Medium as a Marker of Oocyte and Embryo Quality
NCT03350009
Changes in the Distribution of Mitochondria During Oocyte Maturation
NCT01501292
Assessment of Myeloid Cell Constitution in the Follicular Fluid of Women Undergoing In-vitro Fertilization
NCT02342106
Novel Evaluation of Aspirated Follicular Fluid
NCT02999555
The Association Between Overweight and Oocyte Diameter in Women Undergoing Vitro Fertilization
NCT01672931
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SCREENING
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
follicular fluid evaluation using spectrophotometer to differentiate high low quality oocytes
Oocyte quality assessment using spectrophotometer
On the OPU (ovum pick-up) day the following blood biochemical markers will be measured as well- Blood interleukins 1-6, cytokine, hormone profile, lipid profile, cortisol.
After collecting the oocytes- the Follicular fluid will be sent for the following tests-
1. mid-infrared spectrometry,
2. P, E2, testosterone, cortisol, cytokines, IL 1-6, lipids, fatty acids.
3. BMP-15, GDF-9 and HSPG2
4. GCMS-Gas Chromatography Mass Spectrophotometer
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oocyte quality assessment using spectrophotometer
On the OPU (ovum pick-up) day the following blood biochemical markers will be measured as well- Blood interleukins 1-6, cytokine, hormone profile, lipid profile, cortisol.
After collecting the oocytes- the Follicular fluid will be sent for the following tests-
1. mid-infrared spectrometry,
2. P, E2, testosterone, cortisol, cytokines, IL 1-6, lipids, fatty acids.
3. BMP-15, GDF-9 and HSPG2
4. GCMS-Gas Chromatography Mass Spectrophotometer
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Undergoing IVF or IVF-ICSI treatment.
* At least five follicles visualized on ultrasound at the time of oocyte retrieval
* Ability to provide written informed consent.
Exclusion Criteria
* Fewer than five follicles at the time of oocyte retrieval.
* Use of donor oocytes.
* Significant medical comorbidities affecting ovarian function.
* Known ovarian malignancy or prior ovarian surgery significantly affecting follicular integrity.
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hillel Yaffe Medical Center
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hille Yaffe Medical Center
Hadera, Israel, Israel
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0069-23-HYMC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.